Investigational Agents for the Treatment of Gram-Negative Bacterial Infections: A Reality Check

ACS Infectious Diseases

Volumn 1, Issue 11, 2016, Pages 509-511

  Bush, Karen ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACORAFLOXACIN; AMINOGLYCOSIDE DERIVATIVE; BAL 30072; BETA LACTAM DERIVATIVE; BETA LACTAMASE INHIBITOR; BRILACIDIN; DELAFLOXACIN; DNA TOPOISOMERASE INHIBITOR; ERAVACYCLINE; FINAFLOXACIN; GEPOTIDACIN; IMIPENEM; LASCUFLOXACIN; LEFAMULIN; MEDI 3902; MUREPAVADIN; OMADACYCLINE; PLAZOMICIN; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RELEBACTAM; RG 6080; S 649266; TETRACYCLINE DERIVATIVE; UNCLASSIFIED DRUG; VABORBACTAM; ZABOFLOXACIN; ZOLIFLODACIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; DRUG APPROVAL; DRUG RESEARCH; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; HUMAN; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW;

EID: 84969145292     PISSN: None     EISSN: 23738227     Source Type: Journal    
DOI: 10.1021/acsinfecdis.5b00100     Document Type: Review

References (10)

1. Boucher, H. W., Talbot, G. H., Benjamin, D. K., Bradley, J., Guidos, R. J., Jones, R. N., Murray, B. E., Bonomo, R. A., and Gilbert, D. (2013) 10 × '20 Progress-development of new drugs active against Gram-negative bacilli: an update from the Infectious Diseases Society of America Clin. Infect. Dis. 56, 1685-1694 10.1093/cid/cit152
2. Bragginton, E. C. and Piddock, L. J. (2014) UK and European Union public and charitable funding from 2008 to 2013 for bacteriology and antibiotic research in the UK: an observational study Lancet Infect. Dis. 14, 857-868 10.1016/S1473-3099(14)70825-4
3. Rex, J. H. (2014) ND4BB: addressing the antimicrobial resistance crisis Nat. Rev. Microbiol. 12, 231-232 10.1038/nrmicro3245
4. Amin, A. N. and Deruelle, D. (2015) Healthcare-associated infections, infection control and the potential of new antibiotics in development in the USA Future Microbiol. 10, 1049-1062 10.2217/fmb.15.33
5. Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States; Atlanta, GA, USA, 2013.
6. Eichberg, M. J. (2015) Public funding of clinical-stage antibiotic development in the United States and European Union Health Security 13, 156-165 10.1089/hs.2014.0081
7. Pucci, M. J. and Bush, K. (2013) Investigational antimicrobial agents of 2013 Clin. Microbiol. Rev. 26, 792-821 10.1128/CMR.00033-13
8. U.S. FDA approves new antibacterial drug Avycaz; http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm435629.htm.
9. Page, M. G. P. and Bush, K. (2014) Discovery and development of new antibacterial agents targeting Gram-negative bacteria in the era of pandrug resistance: is the future promising? Curr. Opin. Pharmacol. 18, 91-97 10.1016/j.coph.2014.09.008
10. Tommasi, R., Brown, D. G., Walkup, G. K., Manchester, J. I., and Miller, A. A. (2015) ESKAPEing the labyrinth of antibacterial discovery Nat. Rev. Drug Discovery 14, 529-542 10.1038/nrd4572